|
US5736577A
(en)
*
|
1995-01-31 |
1998-04-07 |
Sepracor, Inc. |
Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
|
|
US3864388A
(en)
*
|
1970-12-29 |
1975-02-04 |
Sumitomo Chemical Co |
Alkynyl esters of {60 -alkoxy-{60 -phenyl alkenoic acid
|
|
US5036107A
(en)
*
|
1986-06-27 |
1991-07-30 |
Marion Merrell Dow Inc. |
1,7-substituted heptyn-2-ones and use
|
|
US4957941A
(en)
*
|
1987-11-16 |
1990-09-18 |
United Pharmaceuticals, Inc. |
Anti-spasmdoic agents having an acetylenic bond
|
|
IL91377A
(en)
*
|
1988-09-14 |
1996-09-12 |
Nippon Shinyaku Co Ltd |
Derivatives of botinylamine glycolate
|
|
US5677346A
(en)
*
|
1995-01-31 |
1997-10-14 |
Sepracor, Inc. |
Treating urinary incontinence using (S)-desethyloxybutynin
|
|
US5532278A
(en)
*
|
1995-01-31 |
1996-07-02 |
Sepracor, Inc. |
Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
|
|
AU3799997A
(en)
*
|
1996-07-09 |
1998-02-02 |
Sepracor, Inc. |
Dextrorotatory isomers of oxybutynin and desethyloxybutynin in the treatment of gastrointestinal hyperactivity
|
|
US6140529A
(en)
*
|
1998-10-22 |
2000-10-31 |
Sepracor Inc. |
Synthesis of optically active cyclohexylphenylglycolate esters
|
|
US5973182A
(en)
*
|
1998-10-22 |
1999-10-26 |
Sepracor Inc. |
Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters
|
|
US7179483B2
(en)
|
2000-04-26 |
2007-02-20 |
Watson Pharmaceuticals, Inc. |
Compositions and methods for transdermal oxybutynin therapy
|
|
CN101305994A
(zh)
*
|
2000-04-26 |
2008-11-19 |
沃特森药物公司 |
最小化与奥昔布宁疗法有关的副作用
|
|
ATE418534T1
(de)
|
2001-10-26 |
2009-01-15 |
Pharmacia & Upjohn Co Llc |
Quaternäre ammoniumverbindungen und deren verwendung als antimuscarinische wirkstoffe
|
|
US7399779B2
(en)
|
2002-07-08 |
2008-07-15 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
|
|
DE60226906D1
(de)
*
|
2002-07-31 |
2008-07-10 |
Ranbaxy Lab Ltd |
3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen
|
|
EP1545508A4
(en)
*
|
2002-08-09 |
2009-11-25 |
Ranbaxy Lab Ltd |
3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
|
|
WO2004018422A1
(en)
*
|
2002-08-23 |
2004-03-04 |
Ranbaxy Laboratories Limited |
Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
|
|
TW200412945A
(en)
|
2002-10-25 |
2004-08-01 |
Upjohn Co |
Quaternary ammonium compounds
|
|
ATE400553T1
(de)
|
2002-12-10 |
2008-07-15 |
Ranbaxy Lab Ltd |
3,6-disubstituierte azabicyclo 3.1.0 - hexanderivative als antagonisten des muscarinrezeptors
|
|
AU2002347552A1
(en)
*
|
2002-12-23 |
2004-07-14 |
Ranbaxy Laboratories Limited |
1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
|
|
US7501443B2
(en)
*
|
2002-12-23 |
2009-03-10 |
Ranbaxy Laboratories Limited |
Flavaxate derivatives as muscarinic receptor antagonists
|
|
US7488748B2
(en)
|
2003-01-28 |
2009-02-10 |
Ranbaxy Laboratories Limited |
3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
EP1618091A1
(en)
*
|
2003-04-09 |
2006-01-25 |
Ranbaxy Laboratories, Ltd. |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
WO2004089899A1
(en)
|
2003-04-10 |
2004-10-21 |
Ranbaxy Laboratories Limited |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
EP1615634B1
(en)
*
|
2003-04-10 |
2007-05-16 |
Ranbaxy Laboratories, Ltd. |
Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
|
|
WO2004089900A1
(en)
*
|
2003-04-11 |
2004-10-21 |
Ranbaxy Laboratories Limited |
Azabicyclo derivatives as muscarinic receptor antagonists
|
|
DE602004018844D1
(de)
*
|
2004-06-16 |
2009-02-12 |
Ranbaxy Lab Ltd |
Als antagonisten des muscarinrezeptors geeignete xanthinderivate
|
|
WO2006018708A2
(en)
*
|
2004-08-19 |
2006-02-23 |
Ranbaxy Laboratories Limited |
Pyrrolidine derivatives as muscarinic receptor antagonists
|
|
WO2006032994A2
(en)
*
|
2004-09-24 |
2006-03-30 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
WO2006035303A1
(en)
*
|
2004-09-29 |
2006-04-06 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
EP1828174A1
(en)
*
|
2004-11-19 |
2007-09-05 |
Ranbaxy Laboratories Limited |
Azabicyclic muscarinic receptor antagonists
|
|
WO2006064304A1
(en)
*
|
2004-12-15 |
2006-06-22 |
Ranbaxy Laboratories Limited |
Acid addition salts of muscarinic receptor antagonists
|
|
WO2006117754A1
(en)
*
|
2005-05-03 |
2006-11-09 |
Ranbaxy Laboratories Limited |
3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
|
|
BRPI0617674A2
(pt)
|
2005-10-19 |
2011-08-02 |
Ranbaxy Lab Ltd |
composições farmacêuticas e seus usos
|
|
US20090010923A1
(en)
*
|
2007-04-24 |
2009-01-08 |
University Of Maryland, Baltimore |
Treatment of cancer with anti-muscarinic receptor agents
|
|
WO2009122429A2
(en)
*
|
2008-02-04 |
2009-10-08 |
Matrix Laboratories Limited |
Crystalline oxybutynin and process for preparing the same
|
|
EP2563123B1
(en)
|
2010-04-30 |
2018-04-25 |
Merck Sharp & Dohme Corp. |
Novel beta 3 adrenergic receptor agonists
|
|
US9907767B2
(en)
|
2010-08-03 |
2018-03-06 |
Velicept Therapeutics, Inc. |
Pharmaceutical compositions and the treatment of overactive bladder
|
|
SG10201506076TA
(en)
|
2010-08-03 |
2015-09-29 |
Altherx Inc |
Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
|
|
SG11201404776PA
(en)
|
2012-02-09 |
2014-09-26 |
Altherx Inc |
Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
|
|
WO2016090168A1
(en)
|
2014-12-03 |
2016-06-09 |
Velicept Therapeutics, Inc. |
Compositions and methods of using modified release solabegron for lower urinary tract symptoms
|
|
PL3365321T3
(pl)
|
2015-10-23 |
2024-03-25 |
B3Ar Therapeutics, Inc. |
Jon obojnaczy solabegronu i jego zastosowania
|
|
KR102874891B1
(ko)
|
2018-01-30 |
2025-10-21 |
애프니메드, 인코포레이티드 (델라웨어) |
수면 무호흡증을 치료하기 위한 방법 및 조성물
|
|
AU2021268618A1
(en)
|
2020-05-05 |
2022-12-15 |
Apnimed, Inc. (Delaware) |
Polymorphic forms of (R)-oxybutynin hydrochloride
|